Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what assessment he has made of the impact of supply chain issues surrounding the importing of Creon into the United Kingdom on patients with pancreatic diseases; and what steps he is taking to increase the amount of Creon being imported into the United Kingdom.

The Department has been working with suppliers to address the current supply issues with Creon, which is a brand of pancreatic enzyme replacement therapy (PERT) used by patients with conditions such as cystic fibrosis and certain cancers, including pancreatic cancer. The supply issues with Creon are impacting countries throughout Europe and have been caused by the limited availability of raw ingredients and manufacturing capacity constraints to produce volumes needed to meet demand. These issues have resulted in knock-on supply disruptions of alternative PERT medications.

The Department is continuing to work with all suppliers of PERT to help resolve the supply issues in the short and longer term by asking that they expedite deliveries, source stock from other markets, and increase production. The Department has also reached out to specialist importers of unlicensed medicine to understand whether they can source unlicensed imports of Creon to help mitigate this supply issue. Where such imports have been sourced, the Department has worked with the Medicines and Healthcare products Regulatory Agency to expedite regulatory processes.